Author:
Zhou Shishi,Song Bingxin,Li Chenghui,Tang Wanfen,Zhang Xia,Jin Xiayun,Xu Xifeng,Wang Qinghua,Zheng Hongjuan,Fu Jianfei
Abstract
AbstractChemotherapy-related thrombocytopenia (CIT) is a significant adverse event during chemotherapy, which can lead to reduced relative dose intensity, increased risk of serious bleeding and additional medical expenditure. Herein, we aimed to develop and validate a predictive nomogram model for prediction of CIT in patients with solid tumor. From Jun 1, 2018 to Sep 9, 2021, a total of 1541 patients who received 5750 cycles of chemotherapy were retrospectively enrolled. Cox regression analysis was performed to identify predictive factors to establish the nomogram model for CIT. The incidence of chemotherapy-induced thrombocytopenia was 21.03% for patient-based and 10.26% for cycles of chemotherapy. The top five solid tumors with CIT are cervix, gastric, bladder, biliary systemic, and ovarian. The incidence of chemotherapy dose delays in any cycle because of CIT was 5.39%. Multivariate analysis showed that tumor site, treatment line, AST, oxaliplatin, and capecitabine were significantly associated with CIT. Moreover, we established a nomogram model for CIT probability prediction, and the model was well calibrated (Hosme-Lemeshow P = 0.230) and the area under the receiver operating characteristic curve was 0.844 (Sensitivity was 0.625, Specificity was 0.901). We developed a predictive model for chemotherapy-induced thrombocytopenia based on readily available and easily assessable clinical characteristics. The predictive model based on clinical and laboratory indices represents a promising tool in the prediction of CIT, which might complement the clinical management of thrombocytopenia.
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics. CA Cancer J. Clin. 71(1), 7–33 (2021).
2. Expert consensus on diagnosis and treatment of chemotherapy-induced thrombocytopenia in cancer patients (2014). Zhonghua zhong liu za zhi Chin. J. Oncol. 36(11):876–879.
3. Epstein, R. S. et al. Patient burden and real-world management of chemotherapy-induced myelosuppression: Results from an online survey of patients with solid tumors. Adv. Ther. 37(8), 3606–3618 (2020).
4. Wu, Y., Aravind, S., Ranganathan, G., Martin, A. & Nalysnyk, L. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: A descriptive study of a large outpatient oncology practice database, 2000–2007. Clin. Ther. 31(Pt 2), 2416–2432 (2009).
5. Hitron, A. et al. Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors. J. Oncol. Pharm. Pract. 17(4), 312–319 (2011).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献